{"nctId":"NCT00830128","briefTitle":"A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia","startDateStruct":{"date":"2009-07"},"conditions":["Fibromyalgia"],"count":106,"armGroups":[{"label":"pregabalin (Lyrica)","type":"EXPERIMENTAL","interventionNames":["Drug: pregabalin (Lyrica)"]}],"interventions":[{"name":"pregabalin (Lyrica)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have met the inclusion criteria for the preceding fibromyalgia Protocol A0081208, and must have received pregabalin/placebo under double-blind conditions.\n\nExclusion Criteria:\n\n* Patients may not participate in the study if they experienced a serious adverse event during the previous fibromyalgia Study A0081208; which was determined to be related to the study medication by the investigator or the sponsor.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events: those which occurred or worsened after baseline. An AE resulting in any of the following outcomes, was considered to be a serious adverse event: death; lifethreatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Endpoint","description":"The pain VAS is a horizontal line; 100 mm in length, self-administered by the patient to rate pain from 0 (no pain) to 100 (worst possible pain). The score indicates the pain intensity during the past 1 week before a visit.\n\nChange = mean scores at observation minus mean scores at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.1","spread":"25.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Disturbance at Endpoint","description":"MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Disturbance subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means greater sleep disturbance.\n\nChange = mean scores at observation minus mean scores at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.6","spread":"23.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Snoring at Endpoint","description":"MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Snoring subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms.\n\nChange = mean scores at observation minus mean scores at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"22.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Awaken Short of Breath or With a Headache at Endpoint","description":"MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Awaken Short of Breath or With a Headache subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms.\n\nChange = mean scores at observation minus mean scores at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"23.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Adequacy at Endpoint","description":"MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Adequacy subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means greater sleep adequacy.\n\nChange = mean scores at observation minus mean scores at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"21.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Quantity of Sleep at Endpoint","description":"MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Quantity of Sleep subscales rated 0 to 24 (number of hours slept). A higher score means greater quantity of sleep.\n\nChange = mean scores at observation minus mean scores at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Somnolence at Endpoint","description":"MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Somnolence subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms.\n\nChange = mean scores at observation minus mean scores at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"24.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Overall Sleep Problems Index at Endpoint","description":"MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Overall Sleep Problems Index rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms.\n\nChange = mean scores at observation minus mean scores at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"15.7"}]}]}]},{"type":"SECONDARY","title":"Medical Outcomes Study (MOS) Sleep Scale - Optimal Sleep at Endpoint","description":"MOS-Sleep is a patient-rated questionnaire to assess sleep quality and quantity. Optimal sleep component is derived from Sleep Quantity average hours of sleep each night during the past 4 weeks. Number of participants with response = YES if sleep quantity is 7 or 8 hours per night or response = NO if sleep quantity is \\< 7 hours per night.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) - Total Scores at Endpoint","description":"FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment.\n\nChange = mean FIQ scores at observation minus mean scores at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":"17.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) - Subscale Score at Endpoint","description":"FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment.\n\nChange = mean FIQ scores at observation minus mean scores at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"2.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":106},"commonTop":["Nasopharyngitis","Somnolence","Dizziness","Constipation","Weight increased"]}}}